At the IDWeek 2023 infectious disease conference held last week in Boston, fungal infections got the audience’s attention during the session titled, “The antifungal evolution: novel strategies for a changing world.” With the emergence of some resistant pathogens such Candida auris and the growing disease burden in the population at risk for life-threatening fungal infections, these pathogens are more than ever standing out within the infectious diseases arena. Read More
KRAS is a GTP-binding protein involved in cell growth control that requires post-translational farnesylation to be active. KRAS G12D mutations are mostly associated with pancreatic, colorectal and non-small-cell lung cancers and occur less commonly in other cancers. There are currently no therapies approved to specifically target this mutation. Read More
Monte Rosa Therapeutics Inc. has entered into a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. to discover and develop molecular glue degraders against targets in cancer and neurological diseases previously considered impossible to drug. Read More
Researchers from Astellas Pharma Inc. presented preclinical data for the novel small-molecule diacylglycerol kinase ζ (DGKζ) inhibitor ASP-1570, currently in phase I development for the treatment of solid tumors (NCT05083481). Read More
Bloomsbury Genetic Therapies Ltd. has announced U.S. and E.U. orphan drug designations for BGT-NPC, an investigational gene therapy for the treatment of Niemann-Pick disease type C (NPC). BGT-NPC is an investigational AAV9 gene therapy designed to provide a potentially curative solution to NPC patients following a one-time injection in the cerebrospinal fluid. Read More
Researchers from Generate Biomedicines Inc. have detailed the discovery and preclinical characterization of GB-0669, a spike S2-targeted monoclonal antibody (MAb) being developed for the prophylaxis of SARS-CoV-2 infection. Machine learning models were used to identify MAbs targeting the conserved S2 stem helix and RBD class IV region of spike. Read More
Y-Mabs Therapeutics Inc. has received FDA clearance of its IND application for CD38-SADA, the company’s second program within its SAYA Y-PRIT (Self-Assembly DisAssembly Pre-targeted Radioimmunotherapy) theranostic platform. Read More
Chengdu Easton Biopharmaceuticals Co. Ltd. has synthesized aminopyridine derivatives acting as CDK9/cyclin T1 inhibitors reported to be useful for the treatment of cancer. Read More
A team at 1st Bio Therapeutics Inc. has identified indazoles acting as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer, autoimmune disease and inflammatory disorders. Read More
Researchers from Biolexis Therapeutics Inc. presented the development of a potent and highly selective CDK9 inhibitor, BLX-3030, and its analogues for the treatment of N-Myc and c-Myc-driven cancers. Read More
Autotelic Bio Inc. has divulged thiazole derivatives acting as TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors reported to be useful for the treatment of cancer. Read More
Ideaya Biosciences Inc. has described piperazine substituted indazole compounds acting as poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer. Read More
Gilead Sciences Inc. and Assembly Biosciences Inc. have entered into a 12-year partnership to advance the research and development of novel antiviral therapies, with an initial focus on Assembly’s established areas of herpesviruses, hepatitis B virus (HBV) and hepatitis D virus (HDV). Read More
Additional early-stage research and drug discovery news in brief, from: Beyond Cancer, Biohaven, Corbus, Destiny, Myricx, Nextcure, Promontory, Storm, Venatorx. Read More
